Novo Nordisk Charts New Course with Strategic Pricing Overhaul

Novo Nordisk slashes U.S. prices for Wegovy & Ozempic from 2027, while preparing for generic competition in Asia after patent expiry. Shareholders approve capital flexibility.

The Danish pharmaceutical giant Novo Nordisk is implementing a fundamental shift in strategy for its key revenue drivers. This dual-pronged approach involves significant price reductions in its crucial U.S. market while simultaneously navigating new generic competition emerging from Asia.

Shareholder Meeting Sets Stage for Future Growth

At its Annual General Meeting held on March 26, shareholders confirmed the company's total share capital of 446.5 million Danish kroner. The Board of Directors also secured enhanced flexibility for future initiatives, retaining authorization until April 2028 to increase capital by up to 44.65 million Danish kroner if required. This move positions the company to fund strategic growth opportunities in the coming years.

U.S. Price Caps Aim to Improve Patient Access

A central pillar of the new strategy is a major repricing initiative for the North American market, set to take effect on January 1, 2027. To broaden patient access, Novo Nordisk will cap the monthly list price for its entire semaglutide portfolio at $675. This represents a substantial reduction: the wholesale price for the weight-loss drug Wegovy will be cut in half, while the price for the diabetes medication Ozempic will fall by 35 percent. The change is particularly targeted at patients whose insurance premiums are directly tied to official list prices or who face high out-of-pocket costs.

Asian Market Braces for Generic Onslaught

The competitive landscape is shifting dramatically in Asia following the expiration of the Indian patent for semaglutide on March 20, 2026. This opens the door for numerous generic drug manufacturers to enter the market. Analysts at Jefferies identify firms including Sun Pharma, Lupin, and Torrent Pharma as being in a prime position to capitalize.

The market anticipates over 40 different generic versions. Injectable formulations are expected to be priced between 1,290 and 4,500 rupees per month. Torrent Pharma is positioning itself as the initial sole provider of an oral variant, which is projected to launch at a 30 to 50 percent discount compared to the original product.

Dividend Adjustment Triggers Technical Share Price Decline

On the trading floor, investors initially reacted with sales on Friday. The share price declined by 4.26 percent, marking a new 52-week low at €30.48. This pullback is largely attributed to a technical factor: the B-shares were traded ex-dividend on March 27. For the past fiscal year, the corporation is distributing an increased dividend of 7.95 Danish kroner per share. The decline was more muted for the U.S.-traded ADRs, which fell by just 1.5 percent, as their ex-dividend date is set for March 30.

With these strategic and financial decisions now in place, Novo Nordisk has outlined its roadmap for navigating the evolving pharmaceutical landscape in the years ahead.